Ticker
ADAP

Price
1.58
Stock movement up
+0.06 (3.95%)
Company name
Adaptimmune Therapeutics Plc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
261.18M
Ent value
400.19M
Price/Sales
9.62
Price/Book
3.19
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
538.58%
1 year return
43.64%
3 year return
-32.99%
5 year return
-16.45%
10 year return
-
Last updated: 2024-03-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ADAP does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales9.62
Price to Book3.19
EV to Sales14.74

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count165.30M
EPS (TTM)-0.17
FCF per share (TTM)-0.17

Income statement

Loading...
Income statement data
Revenue (TTM)27.15M
Gross profit (TTM)27.15M
Operating income (TTM)-136.72M
Net income (TTM)-165.46M
EPS (TTM)-0.17
EPS (1y forward)-0.52

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-503.62%
Profit margin (TTM)-609.46%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash108.03M
Net receivables7.43M
Total current assets255.37M
Goodwill0.00
Intangible assets442.00K
Property, plant and equipment0.00
Total assets328.92M
Accounts payable4.75M
Short/Current long term debt23.08M
Total current liabilities64.50M
Total liabilities247.04M
Shareholder's equity81.88M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-141.77M
Capital expenditures (TTM)29.50M
Free cash flow (TTM)-171.26M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-202.08%
Return on Assets-50.30%
Return on Invested Capital-195.56%
Cash Return on Invested Capital-202.43%

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.55
Daily high1.63
Daily low1.47
Daily Volume1.18M
All-time high21.12
1y analyst estimate5.86
Beta2.21
EPS (TTM)-0.17
Dividend per share-
Ex-div date-
Next earnings date6 May 2024

Downside potential

Loading...
Downside potential data
ADAPS&P500
Current price drop from All-time high-92.52%-
Highest price drop-97.97%-56.47%
Date of highest drop20 Nov 20239 Mar 2009
Avg drop from high-73.70%-11.36%
Avg time to new high448 days13 days
Max time to new high2211 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ADAP (Adaptimmune Therapeutics Plc) company logo
Marketcap
261.18M
Marketcap category
Small-cap
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Employees
534
Investor relations
-
SEC filings
CEO
Adrian Rawcliffe
Country
USA
City
Abingdon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...